BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 21970878)

  • 1. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer.
    Lecharpentier A; Vielh P; Perez-Moreno P; Planchard D; Soria JC; Farace F
    Br J Cancer; 2011 Oct; 105(9):1338-41. PubMed ID: 21970878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
    Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
    Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
    Acheampong E; Morici M; Abed A; Bowyer S; Asante DB; Lin W; Millward M; Gray ES; Beasley AB
    J Cancer Res Clin Oncol; 2023 May; 149(5):1941-1950. PubMed ID: 35896898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC.
    Zhang Y; Men Y; Wang J; Xing P; Zhao J; Li J; Xu D; Hui Z; Cui W
    J Cancer Res Clin Oncol; 2022 May; 148(5):1137-1146. PubMed ID: 34255149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.
    Morrow CJ; Trapani F; Metcalf RL; Bertolini G; Hodgkinson CL; Khandelwal G; Kelly P; Galvin M; Carter L; Simpson KL; Williamson S; Wirth C; Simms N; Frankliln L; Frese KK; Rothwell DG; Nonaka D; Miller CJ; Brady G; Blackhall FH; Dive C
    Ann Oncol; 2016 Jun; 27(6):1155-1160. PubMed ID: 27013395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
    Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
    Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
    Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
    J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice.
    Milano A; Mazzetta F; Valente S; Ranieri D; Leone L; Botticelli A; Onesti CE; Lauro S; Raffa S; Torrisi MR; Marchetti P
    Anal Cell Pathol (Amst); 2018; 2018():3506874. PubMed ID: 29682444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.
    Liu DG; Xue L; Li J; Yang Q; Peng JZ
    Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method.
    Hofman V; Ilie MI; Long E; Selva E; Bonnetaud C; Molina T; Vénissac N; Mouroux J; Vielh P; Hofman P
    Int J Cancer; 2011 Oct; 129(7):1651-60. PubMed ID: 21128227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
    Yang L; Lv Z; Xia W; Zhang W; Xin Y; Yuan H; Chen Y; Hu X; Lv Y; Xu Q; Weng X; Ni C
    Clin Transl Oncol; 2018 Jul; 20(7):912-921. PubMed ID: 29243075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition.
    Kapeleris J; Müller Bark J; Ranjit S; Richard D; Vela I; O'Byrne K; Punyadeera C
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3501-3510. PubMed ID: 35932303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
    Yang L; Yan X; Chen J; Zhan Q; Hua Y; Xu S; Li Z; Wang Z; Dong Y; Zuo D; Xue M; Tang Y; Herschman HR; Lu S; Shi Q; Wei W
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.